Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 7
Submit an article Journal homepage
1,490
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies

Anthony R. MatoLeukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesView further author information
, MD, MSCE,
Jennifer C. SampAbbVie, Inc., North Chicago, IL, United StatesCorrespondence[email protected]
View further author information
, PharmD, PhD,
Geneviève GauthierAnalysis Group, Inc., Montreal, Quebec, CanadaView further author information
, MSc,
Emi TerasawaAnalysis Group, Inc., New York, United StatesView further author information
, PhD &
Danielle M. BranderDivision of Hematologic Malignancies & Cellular Therapy, Duke University, Durham, NC, United StatesView further author information
, MD
Pages 636-643 | Received 06 Feb 2018, Accepted 03 Mar 2018, Published online: 30 Apr 2018

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xiaoxiao Lu, Bruno Emond, Zaina P. Qureshi, Linda H. Wu, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang & Kerry A. Rogers. (2023) Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma. Current Medical Research and Opinion 39:9, pages 1227-1235.
Read now
Pek Sang Chloe Tang & Constantine Tam. (2019) Managing patients with ibrutinib-resistant CLL: don’t stop ibrutinib until you are ready with the next therapy. Leukemia & Lymphoma 60:11, pages 2602-2603.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.